Comparative Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Reducing Intraocular Pressure in Patients with Primary Open-Angle Glaucoma

ORIGINAL ARTICLE
Gentian Hoxha, Fëllanza Ismajli Hoxha, Flaka Shoshi

 
For citation: Hoxha G, F Hoxha FI, Shoshi F. Comparative Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Reducing Intraocular Pressure in Patients with Primary Open-Angle Glaucoma. International Journal of Biomedicine. 2025;15(3):527-530. doi:10.21103/Article15(3)_OA11
 
Originally published September 5, 2025

Abstract: 

Background: Glaucoma is a progressive optic neuropathy in which increased intraocular pressure (IOP) is a primary risk factor, leading to vision loss. The present study was initiated to compare the intraocular pressure (IOP)-lowering efficacy of 0.03% bimatoprost and 0.004% travoprost in patients with unilateral primary open-angle glaucoma (POAG).
Methods and Results: A total of 100 patients with POAG were treated with a single hypotensive agent during a 6-month follow-up period. The patients were divided into two groups. Group 1 patients (n=50) were treated with 0.03% bimatoprost, and Group 2 patients (n=50) were treated with 0.004% travoprost. We assessed the IOP at baseline, 1 week, 4 weeks, 12 weeks, and 6 months after treatment. 
There were no significant differences between the two treatments at the initial stage. At 1 week and 4 weeks after treatment, the mean IOP significantly decreased from baseline in both groups. There were no significant differences between the two treatments at these stages. 
After 12 weeks of treatment, IOP continued to decrease effectively in both groups; however, 0.03% bimatoprost provided lower IOP values, and there was a significant difference between groups. In the bimatoprost group, compared to baseline, the reduction was 30.9%, while in the travoprost group, the reduction was 28.3% (P=0.043). The difference was greater after 6 months: in the bimatoprost group, the reduction was 33.0% compared to baseline, while in the travoprost group, the reduction was 29.7% (P=0.033).
Conclusion: The consistently lower IOP values for 0.03% bimatoprost treatment suggest it may be more effective in lowering IOP than 0.004% travoprost.

Keywords: 
glaucoma • intraocular pressure • bimatoprost • travoprost
References: 
  1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002 Oct;120(10):1268-79. doi: 10.1001/archopht.120.10.1268. PMID: 12365904.
  2. Cantor LB, Hoop J, Morgan L, Wudunn D, Catoira Y; Bimatoprost-Travoprost Study Group. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol. 2006 Nov;90(11):1370-3. doi: 10.1136/bjo.2006.094326. Epub 2006 Jul 6. PMID: 16825272; PMCID: PMC1857505.
  3. Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K, Whitcup SM; Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002 Oct;120(10):1286-93. doi: 10.1001/archopht.120.10.1286. PMID: 12365906.
  4. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000 Apr-Jun;10(2):95-104. doi: 10.1177/112067210001000201. PMID: 10887918.
  5. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA; Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001 Oct;132(4):472-84. doi: 10.1016/s0002-9394(01)01177-1. PMID: 11589866.
  6. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005 Jul;112(7):1177-85. doi: 10.1016/j.ophtha.2005.01.042. PMID: 15921747.
  7. McKee HD, Gupta MS, Ahad MA, Saldaña M, Innes JR. First-choice treatment preferences for primary open-angle glaucoma in the United Kingdom. Eye (Lond). 2005 Aug;19(8):923-4. doi: 10.1038/sj.eye.6701674. PMID: 15375365.
  8. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM; Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003 Jan;135(1):55-63. doi: 10.1016/s0002-9394(02)01827-5. PMID: 12504698.
  9. Simmons ST, Dirks MS, Noecker RJ. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Adv Ther. 2004 Jul-Aug;21(4):247-62. doi: 10.1007/BF02850157. PMID: 15605619.
  10. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001 May;45 Suppl 4:S347-51. doi: 10.1016/s0039-6257(01)00213-2. PMID: 11434937.
  11. Orengo-Nania S, Landry T, Von Tress M, Silver LH, Weiner A, Davis AA; Travoprost Study Group. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol. 2001 Dec;132(6):860-8. doi: 10.1016/s0002-9394(01)01257-0. PMID: 11730649.
  12. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003 May;135(5):688-703. doi: 10.1016/s0002-9394(03)00098-9. PMID: 12719078.
  13. Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, Li T, Mansberger SL; American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. Primary Open-Angle Glaucoma Preferred Practice Pattern®. Ophthalmology. 2021 Jan;128(1):P71-P150. doi: 10.1016/j.ophtha.2020.10.022. Epub 2020 Nov 12. PMID: 34933745.
  14. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 2003 Mar;110(3):609-14. doi: 10.1016/S0161-6420(02)01891-2. PMID: 12623831.
  15. Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther. 2002 Nov-Dec;19(6):275-81. doi: 10.1007/BF02853173. PMID: 12665048.
  16. Kaback M, Geanon J, Katz G, Ripkin D, Przydryga J; START Study Group. Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost. Curr Med Res Opin. 2004 Sep;20(9):1341-5. doi: 10.1185/030079904125004448. PMID: 15383181.
  17. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 2: Classification and terminologySupported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 2 Classification and Terminology. Br J Ophthalmol. 2017 May;101(5):73-127. doi: 10.1136/bjophthalmol-2016-EGSguideline.002. Epub 2017 Apr 18. PMID: 28424171; PMCID: PMC5583685.
  18. Macky TA. Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study. J Ocul Pharmacol Ther. 2010 Dec;26(6):605-10. doi: 10.1089/jop.2010.0068. Epub 2010 Oct 29. PMID: 21034177.

Download Article
Received July 15, 2025.
Accepted August 24, 2025.
©2025 International Medical Research and Development Corporation.